Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference
Monday, January 6, 2025 1 min read
Key Takeaway: Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 13, 2025. The presentation will showcase the company's efforts in developing therapeutic medicines for significant unmet medical needs. A live webcast of the event will be available through Kiniksa's website, with a replay accessible 48 hours post-event.
Market Sentiment Analysis
POSITIVE FACTORS
Kiniksa Pharmaceuticals is presenting at a prestigious event, the J.P. Morgan Healthcare Conference.
The company focuses on unmet medical needs with therapeutic medicines.
Kiniksa's immune-modulating assets have strong biological rationale and validated mechanisms.
Full Press Release Details
LONDON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.